In silico prescription of anticancer drugs to cohorts of 28 tumor types reveals targeting opportunities.
暂无分享,去创建一个
Michael P. Schroeder | A. Gonzalez-Perez | N. López-Bigas | C. Rubio-Perez | D. Tamborero | Christian Perez-Llamas | Jordi Deu-Pons | M. P. Schroeder | J. Mestres | A. Antolin | A. González-Pérez
[1] B. Karlan,et al. A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer , 2002, Cancer Gene Therapy.
[2] T. Hubbard,et al. A census of human cancer genes , 2004, Nature Reviews Cancer.
[3] R. Solé,et al. Data completeness—the Achilles heel of drug-target networks , 2008, Nature Biotechnology.
[4] A. Hopkins. Network pharmacology: the next paradigm in drug discovery. , 2008, Nature chemical biology.
[5] A. Ashworth,et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. , 2009, The New England journal of medicine.
[6] David J. Arenillas,et al. Global mapping of binding sites for Nrf2 identifies novel targets in cell survival response through ChIP-Seq profiling and network analysis , 2010, Nucleic acids research.
[7] Gary D Bader,et al. International network of cancer genome projects , 2010, Nature.
[8] G. Getz,et al. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers , 2011, Genome Biology.
[9] H. Mackay,et al. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[11] M. Stratton. Exploring the Genomes of Cancer Cells: Progress and Promise , 2011, Science.
[12] A. Gonzalez-Perez,et al. Functional impact bias reveals cancer drivers , 2012, Nucleic acids research.
[13] B. Al-Lazikani,et al. Combinatorial drug therapy for cancer in the post-genomic era , 2012, Nature Biotechnology.
[14] John P. Overington,et al. ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..
[15] Bissan Al-Lazikani,et al. canSAR: an integrated cancer public translational research and drug discovery resource , 2011, Nucleic Acids Res..
[16] Sahdeo Prasad,et al. Cancer drug discovery by repurposing: teaching new tricks to old dogs. , 2013, Trends in pharmacological sciences.
[17] Gary D Bader,et al. Computational approaches to identify functional genetic variants in cancer genomes , 2013, Nature Methods.
[18] S. Elledge,et al. Cumulative Haploinsufficiency and Triplosensitivity Drive Aneuploidy Patterns and Shape the Cancer Genome , 2013, Cell.
[19] Michael P. Schroeder,et al. IntOGen-mutations identifies cancer drivers across tumor types , 2013, Nature Methods.
[20] K. Kinzler,et al. Cancer Genome Landscapes , 2013, Science.
[21] Benjamin J. Raphael,et al. Mutational landscape and significance across 12 major cancer types , 2013, Nature.
[22] E. Lander,et al. Lessons from the Cancer Genome , 2013, Cell.
[23] Levi A Garraway,et al. Genomics-driven oncology: framework for an emerging paradigm. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] J. Maciejewski,et al. Patterns of missplicing due to somatic U2AF1 mutations in myeloid neoplasms. , 2013, Blood.
[25] Steven A. Roberts,et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes , 2013 .
[26] David Tamborero,et al. OncodriveCLUST: exploiting the positional clustering of somatic mutations to identify cancer genes , 2013, Bioinform..
[27] Jo Wixon,et al. Gene therapy clinical trials worldwide to 2012 – an update , 2013, The journal of gene medicine.
[28] Krister Wennerberg,et al. Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. , 2013, Cancer discovery.
[29] Gary D Bader,et al. Comprehensive identification of mutational cancer driver genes across 12 tumor types , 2013, Scientific Reports.
[30] Steven A. Roberts,et al. Mutational heterogeneity in cancer and the search for new cancer genes , 2014 .
[31] Joshua M. Stuart,et al. The Cancer Genome Atlas Pan-Cancer analysis project , 2013, Nature Genetics.
[32] David Tamborero,et al. OncodriveROLE classifies cancer driver genes in loss of function and activating mode of action , 2014, Bioinform..
[33] D. Lane,et al. Drugging the p53 pathway: understanding the route to clinical efficacy , 2014, Nature Reviews Drug Discovery.
[34] Rodrigo Dienstmann,et al. Standardized decision support in next generation sequencing reports of somatic cancer variants , 2014, Molecular oncology.
[35] S. Gabriel,et al. Discovery and saturation analysis of cancer genes across 21 tumor types , 2014, Nature.
[36] Chandra Sekhar Pedamallu,et al. A Pan-Cancer Analysis of Transcriptome Changes Associated with Somatic Mutations in U2AF1 Reveals Commonly Altered Splicing Events , 2014, PloS one.
[37] M. Sanchez-Cespedes,et al. The SWI/SNF genetic blockade: effects in cell differentiation, cancer and developmental diseases , 2014, Oncogene.
[38] D. Lane,et al. Drugging the p53 pathway: understanding the route to clinical efficacy , 2014, Nature Reviews Drug Discovery.
[39] Dennis C. Friedrich,et al. Whole-exome sequencing and clinical interpretation of formalin-fixed , paraffin-embedded tumor samples to guide precision cancer medicine , 2014 .
[40] Alfonso Valencia,et al. Transcriptome characterization by RNA sequencing identifies a major molecular and clinical subdivision in chronic lymphocytic leukemia , 2014, Genome research.
[41] N. McGranahan,et al. Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. , 2015, Cancer cell.
[42] R. Verhaak,et al. The landscape and therapeutic relevance of cancer-associated transcript fusions , 2014, Oncogene.